36 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Negrin, Hematologist in Stanford, CA?
Dr. Robert Negrin, MD is a Hematologist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 36 years and is board certified by the American Board of Internal Medicine. Dr. Negrin completed his residency at Stanford University School of Medicine. Dr. Negrin is fluent in English and Spanish, and is currently seeing new patients. Dr. Negrin’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Negrin’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Negrin?
Dr. Robert Negrin, MD is a highly-rated, board-certified Hematologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Negrin empowers patients to confidently navigate their health journey, specializing in Bone Marrow Transplant, Hematologic Malignancies, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Negrin is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Negrin go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University School of Medicine
Is Dr. Negrin board certified in Hematologist?
Yes, Dr. Robert Negrin, MD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 1992, American Board of Internal Medicine since 1987
What languages does Dr. Negrin speak?
Dr. Negrin and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does Dr. Negrin treat?
As a Hematologist, Dr. Negrin diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Negrin. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Acute Myeloid Leukemia in Remission
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Acute Myeloid Leukemia in Relapse
- Acute Lymphocytic Leukemia in Remission
- Chronic Myelomonocytic Leukemia
- Chronic Myelogenous Leukemia Treatment (PDQ®)
- Acute Lymphocytic Leukemia
- Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)
- AML Leukemia in Remission
- Acute Myeloblastic Leukemia in Remission
- Acute Myelogenous Leukemia in Remission
- AML Leukemia
- Acute Myeloblastic Leukemia
- Acute Myelogenous Leukemia
- CML
- Chronic myelogenous leukemia
- Philadelphia chromosome positive leukemia
- AML Leukemia in Relapse
- Acute Myeloblastic Leukemia in Relapse
- Acute Myelogenous Leukemia in Relapse
- ALL Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Childhood Leukemia in Remission
- CMML
- Myelomonocytic Leukemia
ICD-10 Codes:
- C9201: Acute myeloblastic leukemia, in remission
- C9200: Acute myeloblastic leukemia, not having achieved remission
- C9210: Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
- C9202: Acute myeloblastic leukemia, in relapse
- C9101: Acute lymphoblastic leukemia, in remission
- C9310: Chronic myelomonocytic leukemia not having achieved remission
Also known as:
- Multiple Myeloma
- Multiple Myeloma in Remission
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
- Plasma Cell Myeloma in Remission', 'Kahler's Disease in Remission
- Myeloma in Remission
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
- C9001: Multiple myeloma in remission
Also known as:
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes Treatment (PDQ®)
- Myelodysplastic Syndromes Treatment (PDQ)
- MDS
- Preleukemia
- Bone marrow failure disorder
- Bone Marrow Failure Syndrome
ICD-10 Codes:
- D469: Myelodysplastic syndrome, unspecified
- D46Z: Other myelodysplastic syndromes
Also known as:
- Bone Marrow Transplant
- Bone Marrow Transplantation
- Stem Cell Transplant
- Hematopoietic Stem Cell Transplant
- Marrow Transplant
ICD-10 Codes:
- Z9481: Bone marrow transplant status
Also known as:
- Chronic Myeloproliferative Neoplasm
- Bone Marrow Disease
- Chronic Myeloproliferative Neoplasms Treatment (PDQ®)
- CMPN
- Myeloproliferative disorder
- Chronic blood cancer
ICD-10 Codes:
- D471: Chronic myeloproliferative disease
Also known as:
- Autologous Stem Cell Donation
- Blood Transfusion and Donation
- Self-stem cell donation
- Donating own stem cells
- Autologous hematopoietic stem cell collection
ICD-10 Codes:
- Z52011: Autologous donor, stem cells
Also known as:
- Hodgkin Lymphoma
- Nodular Sclerosis Hodgkin Lymphoma
- Hodgkin's Disease', 'Hodgkin's Lymphoma
- NSHL', 'Nodular sclerosing Hodgkin's disease
ICD-10 Codes:
- C8190: Hodgkin lymphoma, unspecified, unspecified site
- C8110: Nodular sclerosis Hodgkin lymphoma, unspecified site
Also known as:
- Stem Cell Donation
- Stem Cells
- Donate stem cells
- Bone marrow donation
- Hematopoietic stem cell donation
ICD-10 Codes:
- Z52001: Unspecified donor, stem cells
Also known as:
- Diffuse Large B-cell Lymphoma
- Lymphoma
- DLBCL
- Aggressive B-cell Lymphoma
- Diffuse B-cell Lymphoma
ICD-10 Codes:
- C8330: Diffuse large B-cell lymphoma, unspecified site
Also known as:
- Cancer Immunotherapy
- Oncology immunotherapy
- Immune therapy for cancer
ICD-10 Codes:
- Z5112: Encounter for antineoplastic immunotherapy
Also known as:
- Myelofibrosis
- Bone Marrow Disease
- Bone Marrow Scarring
- Primary Myelofibrosis
ICD-10 Codes:
- D7581: Myelofibrosis
Which procedures does Dr. Negrin perform as a Hematologist?
As a Hematologist, procedures performed by a Dr. Robert Negrin may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Negrin's office.
Does Dr. Negrin accept my insurance?
Dr. Negrin accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Negrin accept in Stanford, CA?
Dr. Negrin in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Imperial Health Plan (CA)
Kaiser Permanente
Medicaid
Medicare
OptumRx
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Negrin's office located?
Recognitions
Publications
Role of lymphocyte activation gene-3
PloS one, 2014
Regulatory T cells and tural killer T cells for modulation of GVHD following allogeneic
Blood, 2013
A distinct evolution of the T
BLOOD, 2013
Mapping immune processes in intact tissues at cellular resolution.
jourl of clinical investigation, 2012
Mapping immune processes in intact tissues at cellular resolution
JOURL OF CLINICAL INVESTIGATION, 2012
Co-transplantation of pure blood stem cells with antigen
PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2012
Low doses of tural killer T cells provide protection from acute graft-versus
BLOOD, 2011
Long-term outcomes in patients with high
BONE MARROW TRANSPLANTATION, 2011
tural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTIL MUCOSA IN ACUTE
Garrote, A. L., Brede, C., Baeuerlein, C., Riedel, S., Kiesel, C., Gre, 2010
Biology and clinical effects of tural killer cells in allogeneic transplantation
CURRENT OPINION IN ONCOLOGY, 2010
Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V
JOURL OF CLINICAL ONCOLOGY, 2010
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation
JOURL OF IMMUNOLOGY, 2009
tural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009
Regulation of different inflammatory diseases by impacting the mevalote pathway
IMMUNOLOGY, 2009
Glycogen synthase kise 3 beta missplicing contributes to leukemia stem cell generation
PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2009
Follicular lymphoma B cells induce the conversion of conventiol CD4
INTERTIOL JOURL OF CANCER, 2009
Impact of mammalian target of rapamycin inhibition on lymphoid homing
JOURL OF IMMUNOLOGY, 2008
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+)
JOURL OF IMMUNOLOGY, 2008
Host-derived interleukin-18 differentially impacts regulatory
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007
A novel technique for the enrichment of primary ovarian cancer cells
AMERICAN JOURL OF OBSTETRICS AND GYNECOLOGY, 2007
CD101 surface expression discrimites potency among murine FoxP3(+) regulatory T cells
JOURL OF IMMUNOLOGY, 2007
In vivo dymics of regulatory T-cell trafficking
BLOOD, 2007
Early CD30 sigling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells
BLOOD, 2007
Role of turally arising regulatory T cells in hematopoietic cell transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.
ture reviews. Immunology, 2006
Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
TURE REVIEWS IMMUNOLOGY, 2006
Protective conditioning for acute graft-versus-host disease - Reply
NEW ENGLAND JOURL OF MEDICINE, 2005
Silencing human NKG2D, DAP10
JOURL OF IMMUNOLOGY, 2005
Ex vivo expanded dendritic cells home to T
AMERICAN JOURL OF PATHOLOGY, 2005
Protective conditioning for acute graft-versus-host disease
NEW ENGLAND JOURL OF MEDICINE, 2005
In vivo alyses of early events in acute graft-versus
BLOOD, 2005
Role of NKG2D sigling in the cytotoxicity of activated and expanded CD8(+) T cells
BLOOD, 2004
CD4(+)CD25(+) regulatory T cells preserve graft-versus
TURE MEDICINE, 2003
Advancing animal models of neoplasia through in vivo bioluminescence imaging
EUROPEAN JOURL OF CANCER, 2002
Visualization of effective tumor targeting by CD8+tural killer T cells redirected with bispecific
CANCER RESEARCH, 2002
Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice
JOURL OF CLINICAL IMMUNOLOGY, 2002
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging
JOURL OF CELLULAR BIOCHEMISTRY, 2002
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence
ANLS OF HEMATOLOGY, 2002
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kise show growth
INTERTIOL JOURL OF CANCER, 2001
Expansion of cytolytic CD8
BLOOD, 2001
Transplantation of bone marrow as compared with peripheral-blood cells from HLA
NEW ENGLAND JOURL OF MEDICINE, 2001
CD2-mediated IL-12-dependent sigls render human gamma delta-T cells resistant to mitogen-induced
BLOOD, 2000
Effect of oral glutamine supplementation during bone marrow transplantation
JOURL OF PARENTERAL AND ENTERAL NUTRITION
Total lymphoid irradiation-antithymocyte globulin conditioning
Biology of blood and marrow transplantation, 2014
Donor hematopoiesis in mice following total lymphoid irradiation requires host T
Blood, 2014
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014
Role of lymphocyte activation gene-3
PloS one, 2014
Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.
Blood, 2013
IL-17 Gene Ablation Does Not Impact Treg
Biology of blood and marrow transplantation, 2013
Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic
Blood, 2013
A distinct evolution of the T
BLOOD, 2013
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third
BLOOD, 2013
Murine anti-third-party central-memory CD8
BLOOD, 2013
A diagnostic window for the treatment of acute graft-versus
BMC medicine, 2013
Cancer Vaccines and T Cell Therapy
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013
Mapping immune processes in intact tissues at cellular resolution.
journal of clinical investigation, 2012
Mapping immune processes in intact tissues at cellular resolution
JOURNAL OF CLINICAL INVESTIGATION, 2012
Prophylactic rituximab after allogeneic transplantation decreases B
BLOOD, 2012
Rapid development of exhaustion
BLOOD, 2012
Co-transplantation of pure blood stem cells with antigen
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2012
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative
BONE MARROW TRANSPLANTATION, 2012
Tandem chemo-mobilization followed by high
BONE MARROW TRANSPLANTATION, 2012
Long-term outcomes after transplantation of HLA
BLOOD, 2012
Cytomegalovirus Viral Load
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012
Adoptive Immunotherapy with Cytokine
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
Role of regulatory T cell populations in controlling graft vs host disease
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2011
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased
BLOOD, 2011
Autologous versus Reduced
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
Low doses of natural killer T cells provide protection from acute graft-versus
BLOOD, 2011
CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity
BLOOD, 2011
Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells
CELL STEM CELL, 2011
Long-term outcomes in patients with high
BONE MARROW TRANSPLANTATION, 2011
Natural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011
CXCL12 Mediates Immunosuppression
CANCER RESEARCH, 2010
Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells
CANCER RESEARCH, 2010
Phase I/II Trial of GN-BVC
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010
CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTINAL MUCOSA IN ACUTE
Garrote, A. L., Brede, C., Baeuerlein, C., Riedel, S., Kiesel, C., Gre, 2010
DIFFERENCES IN ALLOREACTIVE T CELL MIGRATION IN MHC MATCHED VERSUS MHC MISMATCHED HCT
Baeuerlein, C., Riedel, S., Brede, C., Garrote, A. L., Kiesel, C., Rit, 2010
NK cells mediate reduction of GVHD by inhibiting activated
BLOOD, 2010
Simultaneous blockade of several endothelial lig
Beilhack, A., Baker, J., Riedel, S., Brede, C., Baeuerlein, C. A., Jor, 2010
Biology and clinical effects of natural killer cells in allogeneic transplantation
CURRENT OPINION IN ONCOLOGY, 2010
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged
BONE MARROW TRANSPLANTATION, 2010
Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V
JOURNAL OF CLINICAL ONCOLOGY, 2010
Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells
STEM CELLS, 2009
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation
JOURNAL OF IMMUNOLOGY, 2009
TLI and ATG conditioning with low risk of graft-versus
BLOOD, 2009
Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009
Regulation of different inflammatory diseases by impacting the mevalonate pathway
IMMUNOLOGY, 2009
Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2009
Follicular lymphoma B cells induce the conversion of conventional CD4
INTERNATIONAL JOURNAL OF CANCER, 2009
Impact of mammalian target of rapamycin inhibition on lymphoid homing
JOURNAL OF IMMUNOLOGY, 2008
In vivo trafficking
BLOOD, 2008
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+)
JOURNAL OF IMMUNOLOGY, 2008
Long-term remission of Philadelphia chromosome
BLOOD, 2008
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008
Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs
BLOOD, 2008
Interleukin-2 receptor downstream events in regulatory T cells
CELL CYCLE, 2008
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation
BLOOD, 2008
Differential impact of mammalian target of rapamycin inhibition on CD4(+)CD25(+)Foxp3(+)
BLOOD, 2008
Preemptive HMG-CoA reductase inhibition provides graft
BLOOD, 2007
Host-derived interleukin-18 differentially impacts regulatory
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007
A novel technique for the enrichment of primary ovarian cancer cells
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007
CD101 surface expression discriminates potency among murine FoxP3(+) regulatory T cells
JOURNAL OF IMMUNOLOGY, 2007
In vivo dynamics of regulatory T-cell trafficking
BLOOD, 2007
Early CD30 signaling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells
BLOOD, 2007
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid
BLOOD, 2007
Promise and challenges of human regulatory T cells in the clinic
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007
Role of naturally arising regulatory T cells in hematopoietic cell transplantation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006
High-dose carmustine, etoposide
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006
Inhibition of CD4(+)CD25(+) regulatory T-cell function by calcineurin
BLOOD, 2006
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.
Nature reviews. Immunology, 2006
Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
NATURE REVIEWS IMMUNOLOGY, 2006
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic
Current stem cell research & therapy, 2006
Synergistic antitumor effects of immune cell-viral biotherapy
SCIENCE, 2006
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine
CLINICAL CANCER RESEARCH, 2006
The apoptotic and proliferative fate of cytokine
CYTOTHERAPY, 2006
Total lymphoid irradiation and transplantation tolerance
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2006
Protective conditioning for acute graft-versus-host disease - Reply
NEW ENGLAND JOURNAL OF MEDICINE, 2005
Silencing human NKG2D, DAP10
JOURNAL OF IMMUNOLOGY, 2005
Ex vivo expanded dendritic cells home to T
AMERICAN JOURNAL OF PATHOLOGY, 2005
Protective conditioning for acute graft-versus-host disease
NEW ENGLAND JOURNAL OF MEDICINE, 2005
In vivo analyses of early events in acute graft-versus
BLOOD, 2005
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection
TRANSPLANTATION, 2005
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine
CLINICAL CANCER RESEARCH, 2005
A phase I trial of autologous cytokine
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005
Hematopoietic stem and progenitor cells
ANNUAL REVIEW OF MEDICINE, 2005
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8(+) T cells
BLOOD, 2004
Evaluation of effector cell fate and function by in vivo bioluminescence imaging
METHODS, 2003
CD4(+)CD25(+) regulatory T cells preserve graft-versus
NATURE MEDICINE, 2003
Revealing lymphoma growth
BLOOD, 2003
Advancing animal models of neoplasia through in vivo bioluminescence imaging
EUROPEAN JOURNAL OF CANCER, 2002
Visualization of effective tumor targeting by CD8+natural killer T cells
CANCER RESEARCH, 2002
Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice
JOURNAL OF CLINICAL IMMUNOLOGY, 2002
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging
JOURNAL OF CELLULAR BIOCHEMISTRY, 2002
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence
ANNALS OF HEMATOLOGY, 2002
Bioluminescence imaging of lymphocyte trafficking in vivo
EXPERIMENTAL HEMATOLOGY, 2001
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth
INTERNATIONAL JOURNAL OF CANCER, 2001
Rapid engraftment after allogeneic transplantation of density
CANCER, 2001
Expansion of cytolytic CD8
BLOOD, 2001
Survivin expression correlates with apoptosis resistance after lymphocyte activation
IMMUNOLOGY LETTERS, 2001
CD58/LFA-3 and IL-12 provided by activated monocytes
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001
Transplantation of bone marrow as compared with peripheral-blood cells from HLA
NEW ENGLAND JOURNAL OF MEDICINE, 2001
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first
BLOOD, 2001
High-dose therapy and autologous hematopoietic
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001
Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001
CD31 mismatching affects marrow transplantation outcome
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001
Efficacy and toxicity of a CCNU-containing high
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001
Engineering hematopoietic grafts
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001
CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced
BLOOD, 2000
Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000
Effect of oral glutamine supplementation during bone marrow transplantation
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
What is Dr. Negrin's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Negrin's National Provider Identifier (NPI) number is 1285791756.
What common questions do patients ask about Dr. Negrin?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Negrin
What is Dr. Robert Negrin's specialty?
Dr. Negrin is a Hematologist near Stanford, CA. An internist with advanced training specializing in disorders of the blood, spleen, and lymphatic system. This specialist manages conditions such as anemia, clotting disorders, sickle cell disease, hemophilia, leukemia, and lymphoma. Contact Dr. Negrin to book an appointment today.
Is this Dr. Robert Negrin affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Negrin is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Hematologist?
Explore Hematologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Robert Negrin accepting new patients in Stanford, CA?
Yes, Dr. Robert Negrin is accepting new patients at this time.
Does Dr. Robert Negrin offer online booking?
Please contact Dr. Negrin's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Robert Negrin?
Please contact Dr. Negrin's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Robert Negrin have?
Dr. Robert Negrin is certified by the American Board of Internal Medicine.
Other Hematologist Near Stanford, CA
Hematologist
Accepting patientsHematologist
Accepting patientsMedical Oncologist
Accepting patients